Search company, investor...

Kamada Pharmaceuticals

kamada.com

Stage

PIPE | IPO

Market Cap

0.67B

About Kamada Pharmaceuticals

Kamada Pharmaceuticals develops, produces and markets a line of specialty life-saving therapeutics using its proprietary chromatographic purification technologies. Kamada is traded on the Tel Aviv Stock Exchange (TASE: KMDA) and the Nasdaq (NASDAQ: KMDA).

Headquarters Location

2 Holzman St Science Park

Rehovot, 7670402,

Israel

+972 8 9406472

Missing: Kamada Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kamada Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Kamada Pharmaceuticals Patents

Kamada Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/21/2018

3/30/2021

Clusters of differentiation, Transcription factors, Lung disorders, EC 3.4.21, Rare diseases

Grant

Application Date

2/21/2018

Grant Date

3/30/2021

Title

Related Topics

Clusters of differentiation, Transcription factors, Lung disorders, EC 3.4.21, Rare diseases

Status

Grant

Latest Kamada Pharmaceuticals News

Japan v Costa Rica: World Cup 2022 – live!

Nov 27, 2022

Minute-by-minute updates on the Group E encounterAny comments? You can email Will or tweet WillJapan (4-2-3-1): Gonda; Yamane, Itakura, Yoshida, Nagatomo; Endo, Morita; Doan, Kamada, Soma; UedaCosta Rica (4-2–2-2): Navas; Watson, Calvo, Duarte, Oviedo; Tejeda, Borges; Fuller, Torres; Campbell, Contreras Continue reading...

Kamada Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kamada Pharmaceuticals Rank

Kamada Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Kamada Pharmaceuticals's headquarters?

    Kamada Pharmaceuticals's headquarters is located at 2 Holzman St, Rehovot.

  • What is Kamada Pharmaceuticals's latest funding round?

    Kamada Pharmaceuticals's latest funding round is PIPE.

  • Who are the investors of Kamada Pharmaceuticals?

    Investors of Kamada Pharmaceuticals include FIMI Opportunity Funds, GlenRock Israel and Hercules Capital.

  • Who are Kamada Pharmaceuticals's competitors?

    Competitors of Kamada Pharmaceuticals include Oxford BioMedica, AM-Pharma, DiaMedica, Innate Pharma, OraPharma and 11 more.

Compare Kamada Pharmaceuticals to Competitors

O
Orphagenix

OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.

V
Vybion

Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

H
Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.